According to the U.S. National Center for Health Statistics, more than 1 million total knee and hip replacement surgeries are performed every year. Because so many individuals rely on medical intervention to keep them mobile, we are committed to the advancement of orthopedic innovation through both biopharmaceutical and medical device and diagnostic development.

Chiltern has a team of orthopedists and other medical professionals who specialize in the full spectrum of musculoskeletal research — adding support and value to your project with their expertise and leadership. Working as a cross-functional group, the team collaborates with you to provide orthopedic advice from medical, operational, regulatory and cost-efficiency perspectives. The relationships they foster with key surgeons and other industry leaders allow them to provide deeper insights and strategic guidance, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals.

Chiltern has experience with numerous types of assessment tools commonly used in orthopedic clinical studies, including, but not limited to, Western Ontario and McMaster Universities Arthritis Index (WOMAC), Patient Activation Measure (PAM13), NRPS, VAMS, AOS, PTGA, COGA, ODI, VAS and SF 36.

We also provide innovative strategies to manage the clinical development life cycle of your orthopedic products and have experience in developing mobile medical applications associated with osteoarthritis.

Over the last five years, Chiltern has conducted 48 orthopedic studies.

Orthopedics 1

Investigators
Patients
Countries
Total Studies

Top Orthopedic Indications From the Past Five Years

  • Ankle sprains
  • Bone fractures
  • Joint disorders & dislocations
  • Lumbar disc herniation
  • Rotator cuff syndrome and bursitis

Let us help you reach your program’s goals with a comprehensive range of collaborative services: